此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RAS-Peptide-Profile Study in Healthy Male Subjects (RAS)

2013年5月8日 更新者:University Hospital, Basel, Switzerland

Single-center, Randomized, Open-label, 3-way Crossover Study to Characterize the RAS-peptide-profile After Single and Repeated Oral Administration of Different RAS-inhibitors in Healthy Male Subjects

The primary objective is the characterization of the RAS peptide profiles after single and repeated oral administration of a renin inhibitor, an ACE inhibitor and an angiotensin receptor blocker in healthy volunteers.

Secondary objectives are the correlation of RAS peptide profiles with pharmacokinetic profiles of the different RAS inhibitors and with pharmacodynamic parameters such as blood pressure and heart rate. Output of the classic RAS system will be assessed using aldosterone concentrations. Fluid and sodium intake will be monitored using sodium concentration and total volume in 24h urine.

研究概览

详细说明

The results of a pilot study have shown that single doses of different RAS inhibitors produce characteristic changes of the RAS peptide profiles. In a first step this finding needs to be verified in a larger number of healthy subjects. Since it is unknown, whether the changes that were observed within hours after a single inhibitor dose are stable over time, the profiles also need to be investigated under steady-state conditions of the different inhibitors. Comparison of RAS peptide profiles after single dose and under steady-state conditions will also allow to detect whether the peptide profiles are altered by compensatory mechanisms.

研究类型

介入性

注册 (实际的)

12

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Basel、瑞士、4031
        • Department Clinical Pharmacology, University Hospital Basel

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Male aged between 18 and 45 years (inclusive) at screening.
  • Body mass index (BMI) between 18 and 28 kg/m2 (inclusive) and body weight at least 50 kg at screening.
  • Systolic blood pressure (SBP) 100-140 mmHg, diastolic blood pressure (DBP) 60-90 mmHg and heart rate (HR) 45-90 bpm (inclusive), measured on the leading arm*, after 5 min in the supine position at screening.
  • Signed informed consent prior to any study-mandated procedure.
  • No clinically significant findings on the physical examination at screening.
  • 12-lead electrocardiogram (ECG) without clinically relevant abnormalities at screening.
  • Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent at screening.
  • Ability to communicate well with the investigator and to understand and comply with the requirements of the study.

    • leading arm right = writing with right hand

Exclusion Criteria:

  • Smoking > 5 cigarettes per day
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Loss of ≥ 250 ml of blood within 3 months prior to screening.
  • Treatment with an investigational drug within 30 days prior to screening.
  • Previous treatment with any prescribed or over the counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of study.
  • Legal incapacity or limited legal capacity at screening.
  • Positive results from urine drug screen at screening.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity.
  • Known hypersensitivity to any excipients of the drug formulations.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:ACEI-ARB-RI
angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
实验性的:ARB-RI-ACEI
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
实验性的:RI-ACEI-ARB
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)
其他名称:
  • angiotensin converting enzyme inhibitor (ACEI)
  • angiotensin receptor antagonist (ARB)
  • renin inhibitor (RI)

研究衡量的是什么?

主要结果指标

结果测量
大体时间
RAS-peptide profile
大体时间:0-192h
0-192h

次要结果测量

结果测量
大体时间
Blood pressure and heart rate
大体时间:0-192 h
0-192 h
Aldosterone concentrations
大体时间:0-192 h
0-192 h

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Manuel Haschke, PD Dr. med.、Clinical Pharmacology, University Hospital Basel

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年11月1日

初级完成 (实际的)

2013年4月1日

研究注册日期

首次提交

2013年1月16日

首先提交符合 QC 标准的

2013年1月16日

首次发布 (估计)

2013年1月18日

研究记录更新

最后更新发布 (估计)

2013年5月13日

上次提交的符合 QC 标准的更新

2013年5月8日

最后验证

2013年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

ACEI-ARB-RI的临床试验

3
订阅